Company intelligence / Profile preview

Spatz FGIA

Fort Lauderdale, Florida, United States

Ownership: Private
Employees: ~5
Development stage: Commercial

Overview

The company’s core technology, the Spatz3 Adjustable Balloon System, is FDA approved, commercially available in over 40 countries, and has demonstrated a 15% average weight loss and 84% success rate in pivotal trials[4]. Nearly 100,000 devices have been implanted worldwide. Latest development includes clinical trials for a next-generation “Spatz4” adjustable balloon[4][10].

Therapeutic areas: Metabolic DisordersEndocrinology
Modalities: Device
Industry: Therapeutic Medical Devices

Drug pipeline

1 asset

Spatz3

Commercial

Indications: Obesity

Partnerships

Biomedics (Mexico distribution partner)[2]

Beyond the preview

Go deeper on Spatz FGIA.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Spatz FGIA.

Explore the full profile